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Abstract 
Background: The most common type of arrhythmia in the United States and in the European 
countries is atrial fibrillation (AF). The prevalence of AF is increasing worldwide with 
advances in technology, better prediction methods and increased awareness among healthcare 
physicians and patients.  Methods: This article summarises the literature on the 
epidemiology of AF worldwide according to continents, age and ethnicity/race, and also 
includes the prevalence of AF in stroke patients.  Results: In Australia, Europe and the USA, 
the current estimated prevalence of AF is about between 1-4%, with lower prevalence evident 
in Asia (0.49%-1.9%). AF prevalence is highest among Whites.  In Western Europe, 
Australia and North America 70% of people with AF are aged >65 years whereas the average 
age of AF patients in other geographical regions is often lower. Conclusions: Although the 
prevalence of AF worldwide is increasing steadily, large variation can be seen between 
studies and countries. Further epidemiological studies should be undertaken globally, 
especially in Asian and African countries so that a better and more accurate picture of the 
incidence and prevalence of AF can be captured, to enable stroke prevention strategies to be 
appropriately implemented to prevent or reduce the risk of stroke, the most severe 
consequence of AF.  
Keywords: atrial fibrillation, epidemiology, prevalence, worldwide, continents, ethnicity, age, 
stroke 
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Introduction  
Atrial fibrillation (AF), the most common form of arrhythmia with clinical 
significance is a major global health burden worldwide.
1
 In the United States (US) and 
European countries, one in every four middle-aged adults will develop AF. Most importantly, 
AF is associated with a five-fold greater risk of stroke, increased risk of death and 
development of heart failure, and a greater risk of hospital admission, with 10-40% of AF 
patients hospitalised annually. Additionally, irrespective of other cardiovascular-related 
conditions, AF patients have poorer quality of life and unfortunately, despite anticoagulation 
for stroke prevention, they can still develop vascular dementia and a decline in cognitive 
function.
2
 
According to the Global Burden of AF,
3
 worldwide, the projected number of people 
with AF in 2010 was 33.5 million, consisting of 20.9 million males (UI, 19.5-22.2 million) 
and 12.6 million females (UI, 12.0-13.7 million), with higher incidence and prevalence rates 
in developed countries (Table 1). Mortality associated with AF globally is higher in females, 
primarily driven by higher mortality among females in developing countries. (Figure 1). This 
article summarises the literature on the epidemiology of AF worldwide according to 
continents, age and ethnicity/race, and also includes the prevalence of AF in stroke patients.   
Methods 
A literature search was performed on PubMed using the following keywords alone or in 
combination: ‘’atrial’’, ‘’fibrillation’’, ‘’incidence’’, ‘’prevalence’’, ‘’stroke’’, ‘’worldwide’’, 
‘’epidemiology’’, ‘’Asian’’, ‘’race’’, ‘’ethnicity’’. The bibliography from Rahman et al1 was 
checked and additional studies on the prevalence of AF worldwide were included. The 
studies were collated according to the year of publication and country, and summarised in 
Tables 2 and 3.  
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Worldwide prevalence of AF by continents  
In Europe, AF currently affects eight million people and is expected to rise 
drastically, 2.3-fold by 2060.
4, 5
 In the United Kingdom projections from the Clinical Practice 
Research Database suggest that AF will affect between 1.3 and 1.8 million people by 2060.
6
 
In the United States, about 3-5 million people are currently affected by AF and by 2050 this 
figure is expected to be greater than 8 million people.
7
 In Australia, Europe and the USA, the 
current estimated prevalence of AF is about between 1-4%.
1, 4
 Table 2 and Figure 2 
illustrates the prevalence of AF in nine countries, stratified by continents worldwide. 
Australia has the highest prevalence of AF i.e., 5.4% followed by Africa 4.6%, although the 
prevalence was lower (0.7%) in another African study by Shavadiva et al
8
, followed by 
Iceland (2.4%) and lowest in Asian countries (0.49%-1.9%).   
A recent review
9
 on AF epidemiology of 58 studies from five Asian (China, Japan, 
South Korea, India, Malaysia) and eight Middle Eastern countries (Turkey, Bahrain, Qatar, 
Kuwait, Saudi Arabia, Oman, United Arab Emirates and Yemen)
9
 reported the annual 
incidence of AF to be 5.38 per 1000 person-years mainly from Chinese, Japanese and Korean 
studies (10 studies in total) 
10-19
 conducted from 1991-2012, with study populations ranging 
from 1485
14
 to 471,446.
12
 Prevalence of AF varies between hospital-based and community-
based studies; being higher in the latter (0.37%-3.56% vs 2.8%-15.8%).
9
 
Differences in the incidence and prevalence rates between studies is likely dependent 
on the time the study was conducted, the design (nationwide studies, medical insurance 
databases etc., retrospective, prospective, cross-sectional) and the study population (age of 
patients, urban compared to remote areas as their risk factors may vary, for example the 
prevalence of rheumatic heart disease is higher in rural populations in India)
20
 which in turn 
effects the  quality of data obtained.
4
 
 5 
Ethnicity, age and prevalence of AF 
The prevalence of AF across different ethnic groups differs, although most of the 
studies investigating these differences have been conducted in the United States. For the 
purpose of this review, ethnicity is classified as White, (European, American) Afro-
Caribbean, (Blacks, Black British, African-American) East Asian, (Chinese, Japanese, 
Malaysian and other Asians) South Asian (Indian, Pakistani, Bangladeshi), Hispanics 
(Hispanic or Latino), and others, as reported in individual studies.
21, 22
  
Table 3 shows the prevalence of AF by race and ethnicity according to 11 studies,
23-33
 
conducted in the United States and one
23
 multicentre study conducted in North America, 
Europe and Asia. In all studies, the prevalence of AF was highest among the Whites 
compared to Afro-Caribbeans, East Asians and Hispanics, ranging from 42%
32
 to 2.5%
31
 
among the Whites, and 21%
31
 to 1.7% 
30
 among Afro-Caribbeans. Only three studies
23, 25, 33
 
reported AF prevalence among East Asians which ranged from 3.9%
25
 to 10.1%,
23
 while only 
one study reported AF prevalence  among  Hispanics (3.9%).
25
 A meta-analysis of 10 studies 
examining the prevalence of AF among African-Americans in the United States compared to 
Whites, concluded that being African-American was associated with a ‘protective effect’ 
from AF (OR 0.51, 95% CI 0.44-0.59, p<0.001). Despite the lower prevalence of AF, 
African-Americans in the US have twice the risk of first ever stroke compared to Whites. 
34
 
In addition to ethnic differences, age distribution of AF diagnosis may also differ 
between regions. More than 70% of AF patients in Western Europe, Australia and North 
America were aged >65 years.
1
 A different pattern in the average age of AF diagnosis is 
evident from other regions whereby AF patients are younger, for example; the mean age of 
AF patients was 57±16 years in the Gulf-SAFE registry from Arabic population,
35
  41±13 
years in an Ethiopian study,
36
 <65 years in 43% of the South Korean population detected with 
AF
1 
and <50 years in 38% of patients from one South-African hospital.
37
 Results from the 
 6 
RE-LY AF registry which enrolled AF patients from the 164 emergency departments 
worldwide to evaluate the differences in the presentation and management of AF, also shows 
some regional variation in terms of age at AF diagnosis; patients from America and Europe 
countries were on average 10-12 years older than those from Africa, India and the Middle 
East.
38
 
Incidence and prevalence of AF in stroke patients 
AF increases the risk of stroke approximately 5 times compared to those without AF.
2
 
An Italian study has shown
39
 the presence of AF in 24.6% of patients (mean age 
78.8±13.3years) with ischemic stroke in a population based study, where AF is more frequent 
in women and patients 80 years or older. In this study, AF was an independent predictor of 
30-day and 1-year mortality in Cox regression analysis.
39
  
Another prospective study in Germany reported an overall prevalence of AF slightly 
higher than the Italian study, i.e., 28.6% in 692 patients with ischemic stroke or transient 
ischemic attack, with prevalence increasing with age.
40
 Hanchate et al reported a similar 
prevalence of AF in the USA in 2013 (i.e., 23% in acute ischaemic stroke patients from eight 
states),
41
 in two European studies (24.6 and 28.6% respectively)
20, 42
  and an Australian study 
(25%; study population 26,960).
43
 However, the prevalence of AF was reportedly lower in 
some Asian countries, approximately 10% in China,
44
 5.8-6% in India,
45, 46
 but higher in 
Japan (32%).
47
  
Sposato et al conducted a meta-analysis of 50 studies in 2015
48
 to estimate the 
proportion of newly diagnosed AF patients experiencing stroke or TIA after undergoing four 
sequential phases of cardiac monitoring; phase 1: ECG at admission, phase 2: continuous 
inpatient ECG, phase 3: Holter monitoring and phase 4: mobile cardiac outpatient telemetry. 
In this study, they reported an overall presence of AF in 23.7% (95% CI 17.2-31.0) of their 
 7 
post-stroke patients and an estimated prevalence of AF in post-stroke patients with either 
known or newly diagnosed AF of about 39.0%, higher than previously reported studies.
48
 
Conclusion  
The prevalence of AF worldwide is increasing steadily although large variation can be 
seen between studies and countries. A larger proportion of ischemic stroke patients are also 
found to have AF either during admission or upon investigation post- discharge that becomes 
a major concern as AF related to stroke has poorer outcomes and prognosis.
2, 4
 This increase 
in the prevalence of AF may be explained by the fact that better prediction methods have 
been used to detect AF
1, 2, 49
 and also greater awareness among physicians and other 
healthcare providers who are able to detect patients with AF during routine check-ups, flu 
injections and also during hospital admissions.  
More epidemiological studies should perhaps be undertaken globally, especially in 
Asian and African countries, in urban and rural areas, so that a more accurate picture of the 
incidence and prevalence of AF can be captured, thereby allowing appropriate 
implementation of stroke prevention strategies to reduce stroke risk and burden.  
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Table 1: Incidence and prevalence of AF and AF- associated mortality rate with 95% uncertainty intervals (UI) (per 100,000) for males and 
females (data extracted from Chugh 2014) 
3
 
 
  1990 2010 1990 2010 
  Male Female  
Incidence of AF 
Globally, all ages 60.7 (49.2-78.5) 77.5 (65.2-95.4) 43.8 (35.9-55.0) 59.5 (49.9-74.9) 
Developed Countries 78.4 (67.5-91.9) 123.4 (107.6-141.5) 52.8 (45.0-62.9) 90.4 (77.8-104.5) 
Developing Countries 50.0 (33.8-76.8) 53.8 (38.7-79.8) 36.0 (24.5-54.7) 40.0 (27.2-62.6) 
 
Prevalence of AF 
Globally, all ages 569.5 (532.8-612.7) 596.2 (558.4-636.7) 359.9 (334.7-392.6) 373.1 (347.9-402.2) 
Developed Countries 608.2 (547.0-693.5) 660.9 (597.1-738.2) 362.5 (329.3-422.3) 387.7 (343.8-450.0) 
Developing Countries 546.6 (503.0-599.6) 656.7 (522.9-617.6) 358.2 (329.8-393.0) 366.1 (337.4-400.8) 
Mortality rate 
Globally, all ages 0.8 (0.5-1.1) 1.6 (1.0-2.4) 0.9 (0.7-1.2) 1.7 (1.4-2.2) 
Developed Countries 1.3 (0.9-1.9) 2.7 (1.9-4.3) 1.1 (1.0-1.3) 2.4 (2.0-3.0) 
Developing 
Countries 0.4 (0.2-0.8) 0.7 (0.4-1.3) 0.7 (0.4-1.4) 1.0 (0.6-1.7) 
AF= atrial fibrillation
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Table 2:  Worldwide prevalence of AF by continent 
Country Study 
Years data 
obtained 
Study design 
Sample size 
Study population 
Prevalence (%) total,  
(men and women) Data source 
Age (SD) 
[Men, women 
(%)] 
Africa 
Africa 
Sliwa et al  
2010 
37
 
2006-2008 
Prospective  
5328 cardiac 
cases 
Hospital-based, 
single centre, urban 
population 
59 (18) 
[39, 61% AF] 
4.6 (†) 
Kenya  
 
Shavadia et al  
2013 
8
 
2008-2010 
Retrospective  
44, 144 
One hospital 
admission in 
Nairobi 
≥18 
[56, 44% AF] 
0.7 (†) 
Asia 
Malaysia 
 
Lim et al  
2016 
50
 
 
2007-2014 
Prospective 
10,805 
 
18 urban, 22 rural 
communities across 
Malaysia 
52.6 (11.6) 
 
0.49 (†) 
Singapore 
 
Yap et al  
2008
51
 
 
† 
Prospective 
1,839 
 
Community-based 
study 
≥55 1.4 (†) 
Thailand 
 
Phrommintikul et 
al 2016 
52
 
† 
Prospective  
1,277 
 
Cross section of 
Maerim District, 
Chiang Mai 
 
≥65 
[45.8, 54.2% 
AF] 
1.9 (†) 
Australia 
Australia 
Ball et al  
2015
53
 
June 2014 6,140,651 
7 international 
epidemiology study 
≥ 55 years 5.35 (5.97, 4.79) 
 14 
Australia 
 
Sturn et al  
2002 
54
 
 
 
2000 
Prospective 
14, 194 
 
50 consecutive 
patients at 321 
general practices 
≥30 
 
 
4.0 (6.0, 4.0) 
 
 
Europe 
England 
Health & Social 
Care Information 
Centre 2014-2015 
55
 
2014-2015 
Retrospective 
56,939,507 
National primary 
care practice 
database 
† 1.6 (†) 
United 
Kingdom 
Lane et al  
2017 
6
 
1998-2010 
Retrospective 
57, 818 
UK Clinical 
Practice Research 
Datalink (CPRD) 
≥18 years 
[51.7, 48.3% 
AF] 
1.26 (1.33, 1.18) per 1000 pt-
yrs [age-adjusted incidence] 
Iceland 
 
Stefansdottir et al 
2011
5
 
1987 -31 December 
2008 
Retrospective 
4905-AF 
cases 
The National 
University Hospital 
of Iceland 
20–99 years 2.4-age and sex standardised 
North America 
USA 
Naccarelli et al 
2009
56
 
2004-2005 
Retrospective 
242, 903 
National databases 
of employer-funded 
insurance and 
Medicare 
≥20 1.1 (†) 
South America 
Brazil 
Marcolino et al 
2015
42
 
Jan-December 2011 
Retrospective 
262 685 
658 municipalities, 
primary Care 
50.3 (19.3) 
[40.4, 59.6] 
1.8 (2.4, 1.3) 
† Not reported 
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Table 3 Prevalence of AF by ethnicity and race 
Country/State  Study  a) Study design  
b) Follow up 
c) Sample size 
Mean age  
study population (SD)  
Prevalence of AF (%) 
Whites Afro-
Caribbeans 
East 
Asians 
Hispanics 
North 
America, 
Europe, Asia 
Lau et al 
2013
23
 
a) Prospective  
b) 2.5 years 
c) 2580 
Europeans: 76.2 (6.6) 
Black African: 75.2 (6.2) 
Chinese: 76.2 (6.7) 
Japanese: 78.4 (7.0) 
18 8.3 10.1 
Chinese, 
9.5 
Japanese 
N/A 
Michigan,  
USA 
Lahiri et al 2011
24
 a) Retrospective 
b) N/A 
c) 1001 
African American: 
33.0% ≥70 
European American: 
35.4% ≥70 
29 19 N/A N/A 
USA Winkelmayer et al 
2011
33
 
a) Cross sectional 
b) 15 years 
c) 2,483,199 
70.9 (11.8) 14 6.5 9.0* N/A 
California,  
USA 
Shen et al 2010
25
 a) Cross-sectional 
b) N/A 
c) 430, 317 
 
White: 70 (64-77) 
Black: 68 (64-74) 
Asian: 67 (63-73) 
Hispanic: 67 (61-71) 
8 3.8 3.9 3.6 
15 U.S states, 
Washington, 
DC 
Marcus et al 
2010
26
 
a) Combination of CHS 
and ARIC study 
b) – 
c) 19, 784 
CHS 
African American: 73 
(6) 
Whites: 73 (6) 
ARIC 
African Americans: 53 
(6) 
Whites: 54 (6) 
 
23 15 N/A N/A 
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Maryland, 
Minnesota, 
Mississippi, N. 
Carolina, USA 
Alonso et al 
2009
27
 
a) Prospective  
b) 228,976 person-years 
c) 15, 407 
Whites: 54.4 (5.7) 
African Americans: 53.6 
(5.8) 
7.9 4.8 N/A N/A 
Ohio,  
USA 
Smith et al 
2006 
28
 
a) Prospective 
b) - 
c) 9671 
- 24 17 N/A N/A 
California,  
USA 
Ruo et al 
2004 
29
 
a) Retrospective and 
prospective 
b) –  
c) 1373 
73 overall 38 20 N/A N/A 
Georgia,  
USA 
Upshaw et al 
2002
30
 
a) Retrospective  
b) – 
c) 2123 
14% age 70-79 7.8 2.5 N/A N/A 
California,  
USA 
Go et al 
2001
31
 
a) Cross sectional 
b) N/A 
c) 17, 974 
71.2 (12.2) whole cohort  2.5 1.7 N/A N/A 
Michigan, 
USA 
Afzal et al 1999
32
 a) Prospective  
b) 6 months 
c) 163 
Blacks: 63.8 (13.7) 
Whites: 70.8 (13.1) 
42 21 N/A N/A 
Pt-yrs = patient years; *Asian Americans; N/A = not applicable 
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Figure legends 
 
Figure 1: AF associated mortality stratified by sex and region (developed and 
developing countries)  
 
Figure 2: Prevalence of AF by continents 
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